Asia Pacific Human Microbiome Market Analysis, Size, and Share by 2025

Historic Data: 2015-2016   |   Base Year: 2017   |   Forecast Period: 2018-2025

Asia Pacific Human Microbiome Market to 2025 - Regional Analysis and Forecasts by Product (Probiotics, Foods, Prebiotics, Medical Foods, Diagnostic Device, Drugs, and Supplements), Disease (Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders, and Others), Application (Therapeutics and Diagnostics), and Country

  • Report Code : TIPRE00003317
  • Category : Life Sciences
  • No. of Pages : 155
Buy Now

The Asia Pacific human microbiome market is expected to reach US$ 207.81 Mn in 2025 from US$ 41.73 in 2017. The market is estimated to grow with a CAGR of 22.8% from 2018-2025.

The growth of the market is driven by the factors such as rising chronic disease due to change in lifestyle and growing interest in human microbiome treatment approach. Whereas, stringent regulatory environment and lack of awareness about human microbiome science is likely to have a negative impact on the growth of the market in the coming years.

Probiotics, prebiotics dietary supplements and foods that contain live microbes have been studied thoroughly to assess their effects on human health. The Gut Health Congress was held in Hong Kong Asia in 2018, the conference explore in detail of diet & personalised nutrition, gastrointestinal microbiome and several case studies with regards to clinical studies, diagnostics studies, treatment methods, biomarker developments, molecular therapy and gastrointestinal diseases. Also, the 5th Microbiome R&D and Business Collaboration Congress was held in Taiwan, Asia in March 2019, the conference focused on recent developments in gut microbiome, skin microbiome, infant, women and oral health, therapeutics, microbiome and diet.

Also, many companies are designing and developing many microbiome therapies. Thus, the increasing focus on human microbiome therapies is the prime factor driving the growth of human microbiome market in the coming years.

Japan is anticipated to lead the adoptions of Human microbiome across the Asia Pacific region through the forecast period. Researchers from Japan are using the outcomes of studies on centenarians in the country to try and produce new products that will replicate the beneficial aspects of their microbiota. The goal of the collaboration is to solve few of the major technological hurdles in advancing stem cell research. Moreover, Cykinso (Tokyo) received the US$ 2.3 million (270 million yen) funds from the Regional Health Care Industry Support Fund, develop and sell Mykinso or a test kit for intestinal flora. The company plans to use the funds for business development purposes, which include using the data collected from the intestinal flora tests to develop a system for offering nutritional guidance. Thus, the investments and the initiatives taken by the government are likely to propel the growth of the market in the forecast period.

Rest Of Asia Pacific Human microbiome Market Revenue and Forecasts to 2027 (US$ Bn)


  • This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

ASIA PACIFIC HUMAN MICROBIOME- MARKET SEGMENTATION


By Product


• Probiotics
• Foods
• Prebiotics
• Medical Foods
• Diagnostic Device
• Drugs
• Supplements


ASIA PACIFIC HUMAN MICROBIOME- MARKET SEGMENTATION



By Disease


• Obesity
• Diabetes
• Autoimmune Disorders
• Cancer
• Mental Disorders
• Others

ASIA PACIFIC HUMAN MICROBIOME- MARKET SEGMENTATION



By Application


• Therapeutics
• Diagnostics

By Country


• U.S.
• Canada
• Mexico

Companies Mentioned


• Enterome
• MicroBiome Therapeutics, LLC
• Rebiotix Inc.
• Yakult Honsha Co., Ltd.
• Osel Inc.
• Vedanta Biosciences, Inc.
• Metabiomics Corporate
• Synthetic Biologics, Inc.
• DuPont
• BiomX Ltd.

Asia Pacific Human Microbiome Report Scope

Report Attribute Details
Market size in 2017 US$ 41.73 Million
Market Size by 2025 US$ 207.81 Million
Global CAGR (2018 - 2025) 22.8%
Historical Data 2015-2016
Forecast period 2018-2025
Segments Covered By Product
  • Probiotics
  • Foods
  • Prebiotics
  • Medical Foods
  • Diagnostic Device
  • Drugs
  • Supplements
By Disease
  • Obesity
  • Diabetes
  • Autoimmune Disorders
  • Cancer
  • Mental Disorders
By Application
  • Therapeutics and Diagnostics
Regions and Countries Covered Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
Market leaders and key company profiles
  • Enterome
  • MicroBiome Therapeutics, LLC
  • Rebiotix Inc.
  • Yakult Honsha Co., Ltd.
  • Osel Inc.
  • Vedanta Biosciences, Inc.
  • Metabiomics Corporate
  • Synthetic Biologics, Inc.
  • DuPont
    • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
    • PEST and SWOT Analysis
    • Market Size Value / Volume - Global, Regional, Country
    • Industry and Competitive Landscape
    • Excel Dataset
    asia-pacific-human-microbiome-market-report-deliverables-img1
    asia-pacific-human-microbiome-market-report-deliverables-img2
    Report Coverage

    Report Coverage

    Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

    Segment Covered

    Segment Covered

    Product, Disease, Application, and Country

    Regional Scope

    Regional Scope

    North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

    Country Scope

    Country Scope

    Australia, China, Japan, South Korea

    Trends and growth analysis reports related to Life Sciences : READ MORE..   

    Asia Pacific Human Microbiome Market
    Connect With Expert

    The List of Companies - Asia Pacific Human Microbiome Market

    1. Enterome
    2. MicroBiome Therapeutics, LLC
    3. Rebiotix Inc.
    4. Yakult Honsha Co., Ltd.
    5. Osel Inc.
    6. Vedanta Biosciences, Inc.
    7. Metabiomics Corporate
    8. Synthetic Biologics, Inc.
    9. DuPont
    10. BiomX Ltd.
    asia-pacific-human-microbiome-market-cagr